The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Association of Time in Range, as Assessed by Continuous Glucose Monitoring, With Diabetic Retinopathy in Type 2 Diabetes
Abstract
OBJECTIVE: Continuous glucose monitoring (CGM) has provided new measures of glycemic control that link to diabetes complications. This study investigated the association between the time in range (TIR) assessed by CGM and diabetic retinopathy (DR). RESEARCH DESIGN AND METHODS: A total of 3,262 patients with type 2 diabetes were recruited. TIR was defined as the percentage of time spent within the glucose range of 3.9–10.0 mmol/L during a 24-h period. Measures of glycemic variability (GV) were assessed as well. DR was determined by using fundus photography and graded as 1) non-DR; 2) mild nonproliferative DR (NPDR); 3) moderate NPDR; or 4) vision-threatening DR (VTDR). RESULTS: The overall prevalence of DR was 23.9% (mild NPDR 10.9%, moderate NPDR 6.1%, VTDR 6.9%). Patients with more advanced DR had significantly less TIR and higher measures of GV (all P for trend <0.01). The prevalence of DR on the basis of severity decreased with ascending TIR quartiles (all P for trend <0.001), and the severity of DR was inversely correlated with TIR quartiles (r = −0.147; P < 0.001). Multinomial logistic regression revealed significant associations between TIR and all stages of DR (mild NPDR, P = 0.018; moderate NPDR, P = 0.014; VTDR, P = 0.019) after controlling for age, sex, BMI, diabetes duration, blood pressure, lipid profile, and HbA1c. Further adjustment of GV metrics partially attenuated these associations, although the link between TIR and the presence of any DR remained significant. CONCLUSIONS: TIR assessed by CGM is associated with DR in type 2 diabetes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Time in range is associated with the risk of microvascular complications and can be used for assessment of glycemic management (57).”
In the citing paper
“These results align with existing literature that emphasizes the clinical benefits of higher TIR, including reduced complications and improved overall health outcomes for individuals with diabetes19,22–24.”
From Impact of digital health interventions on glycemic control and weight management. (2025) · cites this paper as [22]
In the citing paper
“Most recently, the beneficial effects of new medications, such as sodium glucose cotransporter-2 (SGLT-2) agents have helped individuals with type 1 diabetes increase TIR (49-51).”
From Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range (2019) · cites this paper as [49]
In the citing paper
“TIR has been found to be strongly associated with the development or progression of diabetic retinopathy and microalbuminuria in type 1 and type 2 DM.16 17”
From Glucose time in range and peripheral neuropathy in type 2 diabetes mellitus and chronic kidney disease (2020) · cites this paper as [17]
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Global prevalence and major risk factors of diabetic retinopathy
Yau, J. W. Y., Rogers, S. L., Kawasaki, R., Lamoureux, E. L., Kowalski, J. W., Bek, T., Chen, S.-J., Dekker, J. M., Fletcher, A., Grauslund, J., et al. (2012) · Diabetes Care · doi:10.2337/dc11-1909 · Cited by 4,985
Wilkinson, C. P., Ferris, F. L., Klein, R. E., Lee, P. P., Agardh, C. D., Davis, M., Dills, D., Kampik, A., Pararajasegaram, R., & Verdaguer, J. T. (2003) · Ophthalmology · doi:10.1016/s0161-6420(03)00475-5 · Cited by 3,743
Monnier, L., Mas, E., Ginet, C., Michel, F., Villon, L., Cristol, J.-P., & Colette, C. (2006) · JAMA · doi:10.1001/jama.295.14.1681 · Cited by 2,444
International consensus on use of continuous glucose monitoring
Danne, T., Nimri, R., Battelino, T., Bergenstal, R. M., Close, K. L., DeVries, J. H., Garg, S., Heinemann, L., Hirsch, I., Amiel, S. A., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1600 · Cited by 2,069 · cited 2×
“However, HbA1c is unreliable in patients with anemia, hemoglobinopathies, or iron deficiency, and in patients who are pregnant (7).”
BackgroundSelf-citationContinuous glucose monitoring and intensive treatment of type 1 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805017 · Cited by 1,559
Ceriello, A., Esposito, K., Piconi, L., Ihnat, M. A., Thorpe, J. E., Testa, R., Boemi, M., & Giugliano, D. (2008) · Diabetes · doi:10.2337/db08-0063 · Cited by 1,310
The Diabetes Control and Complications Trial Research Group (1995) · Diabetes · doi:10.2337/diab.44.8.968 · Cited by 1,301
Bolinder, J., Antuna, R., Geelhoed-Duijvestijn, P., Kröger, J., & Weitgasser, R. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31535-5 · Cited by 893
Quagliaro, L., Piconi, L., Assaloni, R., Martinelli, L., Motz, E., & Ceriello, A. (2003) · Diabetes · doi:10.2337/diabetes.52.11.2795 · Cited by 769
Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes
Bergenstal, R. M., Garg, S., Weinzimer, S. A., Buckingham, B. A., Bode, B. W., Tamborlane, W. V., & Kaufman, F. R. (2016) · JAMA · doi:10.1001/jama.2016.11708 · Cited by 644 · cited 2×
“70% by using advanced diabetes technologies suchas theMedtronic MiniMed 670G Insulin Pump System (31).”
MethodBeck, R. W., Riddlesworth, T. D., Ruedy, K., Ahmann, A., Haller, S., Kruger, D., McGill, J. B., Polonsky, W., Price, D., Aronoff, S., et al. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2855 · Cited by 635
Haak, T., Hanaire, H., Ajjan, R., Hermanns, N., Riveline, J.-P., & Rayman, G. (2017) · Diabetes Therapy · doi:10.1007/s13300-016-0223-6 · Cited by 623
Glycemic Variability: A Hemoglobin A1c–Independent Risk Factor for Diabetic Complications
Brownlee, M., & Hirsch, I. B. (2006) · JAMA · doi:10.1001/jama.295.14.1707 · Cited by 482
Intermittent high glucose enhances apoptosis in human umbilical vein endothelial cells in culture
Risso, A., Mercuri, F., Quagliaro, L., Damante, G., & Ceriello, A. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.281.5.e924 · Cited by 425
A1C Variability and the Risk of Microvascular Complications in Type 1 Diabetes
Kilpatrick, E. S., Rigby, A. S., & Atkin, S. L. (2008) · Diabetes Care · doi:10.2337/dc08-0864 · Cited by 420
Racial Differences in the Relationship of Glucose Concentrations and Hemoglobin A1c Levels
Bergenstal, R. M., Gal, R. L., Connor, C. G., Gubitosi-Klug, R., Kruger, D., Olson, B. A., Willi, S. M., Aleppo, G., Weinstock, R. S., Wood, J., et al. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2596 · Cited by 306
Su, G., Mi, S., Tao, H., Li, Z., Yang, H., Zheng, H., Zhou, Y., & Ma, C. (2011) · Cardiovascular Diabetology · doi:10.1186/1475-2840-10-19 · Cited by 257
Cardoso, C. R. L., Leite, N. C., Moram, C. B. M., & Salles, G. F. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0677-0 · Cited by 222
Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes
Sands, A. T., Zambrowicz, B. P., Rosenstock, J., Lapuerta, P., Bode, B. W., Garg, S. K., Buse, J. B., Banks, P., Heptulla, R., Rendell, M., et al. (2015) · Diabetes Care · doi:10.2337/dc14-2806 · Cited by 220
Di Flaviani, A., Picconi, F., Di Stefano, P., Giordani, I., Malandrucco, I., Maggio, P., Palazzo, P., Sgreccia, F., Peraldo, C., Farina, F., et al. (2011) · Diabetes Care · doi:10.2337/dc11-0034 · Cited by 179
Tamborlane, W. V., Bode, B. W., Buckingham, B. A., Chase, H. P., Clemons, R. D., Fox, L. A., Gilliam, L. K., Hirsch, I. B., Huang, E. S., Kollman, C., et al. (2008) · Cited by 167
Horvath, E. M., Benkő, R., Kiss, L., Murányi, M., Pék, T., Fekete, K., Bárány, T., Somlai, Á., Csordás, A., & Szabó, C. (2009) · Diabetologia · doi:10.1007/s00125-009-1304-0 · Cited by 133
Sartore, G., Chilelli, N. C., Burlina, S., & Lapolla, A. (2013) · Acta Diabetologica · doi:10.1007/s00592-013-0459-9 · Cited by 130
Bergenstal, R. M., Bailey, T. S., Rodbard, D., Ziemen, M., Guo, H., Muehlen-Bartmer, I., & Ahmann, A. (2017) · Diabetes Care · doi:10.2337/dc16-0684 · Cited by 123
Ethnic Differences in Glycemic Markers in Patients With Type 2 Diabetes
Wolffenbuttel, B. H. R., Herman, W. H., Gross, J. L., Dharmalingam, M., Jiang, H. H., & Hardin, D. S. (2013) · Diabetes Care · doi:10.2337/dc12-2711 · Cited by 95
on behalf of the FinnDiane Study Group, Hietala, K., Wadén, J., Forsblom, C. M., Harjutsalo, V., Kytö, J., Summanen, P. A., & Groop, P. (2013) · Diabetologia · doi:10.1007/s00125-012-2816-6 · Cited by 72
Matsutani, D., Sakamoto, M., Iuchi, H., Minato, S., Suzuki, H., Kayama, Y., Takeda, N., Horiuchi, R., & Utsunomiya, K. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0683-2 · Cited by 52
Jiménez, A., Ceriello, A., Casamitjana, R., Flores, L., Viaplana-Masclans, J., & Vidal, J. (2014) · Annals of Surgery · doi:10.1097/sla.0000000000000586 · Cited by 51
Lind, M., Polonsky, W. H., Hirsch, I. B., Heise, T., Bolinder, J., Dahlqvist, S., Pehrsson, N.-G., & Moström, P. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816642578 · Cited by 27
Alberti (1998) · doi:10.1002/(sici)1096-9136(199807)15:7<539::aid-dia668>3.0.co;2-s
Cited by
Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R., Biester, T., Bosi, E., Buckingham, B. A., Cefalu, W. T., Close, K. L., et al. (2019) · Diabetes Care · doi:10.2337/dci19-0028 · Cited by 4,237
Self-citationDavies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05787-2 · Cited by 1,048
Continuous glucose monitoring and metrics for clinical trials: an international consensus statement
Battelino, T., Alexander, C. M., Amiel, S. A., Arreaza-Rubin, G., Beck, R. W., Bergenstal, R. M., Buckingham, B. A., Carroll, J., Ceriello, A., Chow, E., et al. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00319-9 · Cited by 831
Screening for diabetic retinopathy: new perspectives and challenges
Vujosevic, S., Aldington, S. J., Silva, P., Hernández, C., Scanlon, P., Peto, T., & Simó, R. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30411-5 · Cited by 671
Metadata
- Authors
- Lu, J., Ma, X., Zhou, J., Zhang, L., Mo, Y., Ying, L., Lu, W., Zhu, W., Bao, Y., Vigersky, R. A., & Jia, W.
- Affiliations
- Shanghai Jiao Tong University (CN)
- Walter Reed National Military Medical Center (US)
- Corresponding author
- Zhou, Jian
- Jia, Weiping
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2018-09-10
- Volume
- 41
- Issue
- 11
- Pages
- 2370-2376
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2891930016
- Cited by
- 517
- References
- 32
- Citations by year
- 2026: 45 · 2025: 55 · 2024: 61 · 2023: 70 · 2022: 87 · 2021: 85 · 2020: 71 · 2019: 40 · 2018: 1
- FWCI
- 39.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (81100590)
- Shanghai Municipal Education Commission (20161430)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- time in range, continuous glucose monitoring, diabetic retinopathy, type 2 diabetes, glycemic variability, glycemic control, non-proliferative diabetic retinopathy, vision-threatening diabetic retinopathy, retinopathy severity
- MeSH terms
- Aged, Blood Glucose, Blood Pressure, Diabetes Mellitus, Type 2, Diabetic Retinopathy, Female, Fundus Oculi, Humans, Male, Middle Aged, Predictive Value of Tests, Prognosis, Reference Values, Retrospective Studies, Time Factors, Blood Glucose Self-Monitoring
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.